Camp4 Therapeutics Corporation (CAMP)

Market Cap	149.12M
Revenue (ttm)	350,000
Net Income (ttm)	-49.71M
Shares Out	19.51M
EPS (ttm)	-111.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,435
Open	8.27
Previous Close	8.12
Day's Range	6.99 - 8.27
52-Week Range	6.99 - 12.30
Beta	n/a
Analysts	Hold
Price Target	16.23 (+112.3%)
Earnings Date	Jan 7, 2025

About CAMP

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001 for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP to treat synaptic Ras GTPase activating protein 1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 11, 2024
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: CAMP
• Website: https://www.camp4tx.com

Financial Performance

Financial numbers in USD

Analyst Forecast

According to 5 analysts, the average rating for CAMP stock is "Hold." The 12-month stock price forecast is $16.23, which is an increase of 112.30% from the latest price.

Price Target

$16.23

(112.30% upside)

Analyst Consensus: Hold